69659
pLysS DNA - Novagen
Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Cambia visualizzazione
| Taglio della confezione | SKU | Disponibilità | Prezzo |
|---|---|---|---|
| 1 μg | Per conoscere la disponibilità, visualizza il carrello | CHF 157.00 |
Informazioni su questo articolo
NACRES:
NA.51
UNSPSC Code:
41106602
CHF 157.00
Per conoscere la disponibilità, visualizza il carrello
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiform
solid
Quality Level
manufacturer/tradename
Novagen®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
shipped in
wet ice
storage temp.
−20°C
General description
pLysS and pLysE are 4886bp plasmids constructed by insertion of the T7 lysozyme gene into the BamH I site of pACYC184 (1). These plasmids are not cloning vectors; they are used in λDE3 lysogenic hosts to suppress basal expression from the T7 promoter by producing T7 lysozyme, a natural inhibitor of T7 RNA polymerase. The two plasmids differ only by the orientation of the T7 lysozyme gene. In pLysS the T7 lysozyme coding sequence is in the antisense orientation relative to the tet promoter, so only a small amount of T7 lysozyme is produced. In pLysE large amounts of T7 lysozyme are produced from the tet promoter. The construct also contains the weak T7 φ3.8 promoter immediately following the lysozyme gene. The p15A origin of replication is compatible with those found in pBR322- and pUC-derived plasmids.
This product is covered under license from Brookhaven National Labs. Commercial entities need to obtain a research use license prior to purchase. Please contact your licensing department to confirm that your company already holds a research use license.
This product is covered under license from Brookhaven National Labs. Commercial entities need to obtain a research use license prior to purchase. Please contact your licensing department to confirm that your company already holds a research use license.
Other Notes
1. Studier , F.W. (1991) J. Mol. Biol. 219, 37-44.
Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
1 of 1
Questo articolo | |||
|---|---|---|---|
| form solid | form liquid | form liquid | form liquid |
| storage temp. −20°C | storage temp. −70°C | storage temp. −70°C | storage temp. −70°C |
| shipped in wet ice | shipped in wet ice | shipped in wet ice | shipped in wet ice |
| storage condition OK to freeze, avoid repeated freeze/thaw cycles | storage condition OK to freeze | storage condition OK to freeze | storage condition OK to freeze |
| manufacturer/tradename Novagen® | manufacturer/tradename Novagen® | manufacturer/tradename Novagen® | manufacturer/tradename Novagen® |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
Classe di stoccaggio
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Contenuto correlato
Numero articolo commerciale globale
| SKU | GTIN |
|---|---|
| 69659-3 | 04055977274479 |